clinical trial · NCT07659795
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Colorectal CancerVS-7375cetuximabpanitumumabCetuximab + mFOLFOX6
brief summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
started
Jul 28, 2026
primary completion
Jun 1, 2027
completion
Dec 1, 2028
last updated
Aug 6, 2026
official title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol